Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company.
Separately, Chardan Capital upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday, May 4th.
Check Out Our Latest Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
